Dr. Pollock's research focuses on the development and evaluation of novel diagnostics for infectious diseases, ranging from early proof of principle laboratory demonstration to field implementation. Her diagnostics research has spanned a range of diseases including C. difficile infection, active and latent tuberculosis, influenza, malaria, Lyme disease, STDs, Ebola virus disease (EVD), and most recently, SARS-CoV-2. Her research has also involved a wide range of technologies, from simple paper-based lateral flow and microfluidic platforms for point-of-care deployment to novel automated platforms for protein and nucleic acid detection.


Dr. Pollock is the Associate Medical Director of the Infectious Diseases Diagnostic Laboratory at Boston Children’s Hospital and a faculty member of the Division of Infectious Diseases at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She is an Associate Professor of Pathology and Medicine at Harvard Medical School. She completed her MD/PhD at the University of California, San Francisco; her medical residency at Brigham and Women’s Hospital in Boston; and her infectious diseases/clinical microbiology fellowships at BIDMC.


Publications powered by Harvard Catalyst Profiles

  1. Detection of Borrelia burgdorferi Cell-free DNA in Human Plasma Samples for Improved Diagnosis of Early Lyme Borreliosis. Clin Infect Dis. 2021 10 05; 73(7):e2355-e2361. View abstract
  2. Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with Clostridioides difficile infection. Clin Infect Dis. 2021 Sep 19. View abstract
  3. Implementation of SARS-CoV2 Screening in K-12 Schools Using In-School Pooled Molecular Testing and Deconvolution by Rapid Antigen Test. J Clin Microbiol. 2021 08 18; 59(9):e0112321. View abstract
  4. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med. 2021 08; 18(8):e1003735. View abstract
  5. Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2. Infection. 2021 Aug 12. View abstract
  6. Lessons Learned From Implementation of SARS-CoV-2 Screening in K-12 Public Schools in Massachusetts. Open Forum Infect Dis. 2021 Aug; 8(8):ofab287. View abstract
  7. Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection. Open Forum Infect Dis. 2021 Jul; 8(7):ofab286. View abstract
  8. The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2-Evaluation of the accuracy and ease-of-use. PLoS One. 2021; 16(5):e0247918. View abstract
  9. Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts. Open Forum Infect Dis. 2021 Jul; 8(7):ofab243. View abstract
  10. The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change. IEEE Open J Eng Med Biol. 2021 Apr 28; 2:142-151. View abstract
  11. Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic Review and Meta-analysis. J Clin Microbiol. 2021 04 20; 59(5). View abstract
  12. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts. J Clin Microbiol. 2021 04 20; 59(5). View abstract
  13. Correlation of SARS-CoV-2 Nucleocapsid Antigen and RNA Concentrations in Nasopharyngeal Samples from Children and Adults Using an Ultrasensitive and Quantitative Antigen Assay. J Clin Microbiol. 2021 03 19; 59(4). View abstract
  14. Considerations for Assessment and Deployment of Rapid Antigen Tests for Diagnosis of Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Jun; 8(6):ofab110. View abstract
  15. Fecal Mycobiota Combined With Host Immune Factors Distinguish Clostridioides difficile Infection From Asymptomatic Carriage. Gastroenterology. 2021 Jun; 160(7):2328-2339.e6. View abstract
  16. To Test, Perchance to Diagnose: Practical Strategies for Severe Acute Respiratory Syndrome Coronavirus 2 Testing. Open Forum Infect Dis. 2021 Apr; 8(4):ofab095. View abstract
  17. Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes. 2021 Jan-Dec; 13(1):1-18. View abstract
  18. Comparison of Upper Respiratory Viral Load Distributions in Asymptomatic and Symptomatic Children Diagnosed with SARS-CoV-2 Infection in Pediatric Hospital Testing Programs. J Clin Microbiol. 2020 12 17; 59(1). View abstract
  19. Molecular detection of Mycobacterium tuberculosis from buccal swabs among adult in Peru. Sci Rep. 2020 12 17; 10(1):22231. View abstract
  20. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci. 2021 10; 66(10):3303-3306. View abstract
  21. Detection of Mycobacterium Tuberculosis DNA in Buccal Swab Samples from Children in Lima, Peru. Pediatr Infect Dis J. 2020 11; 39(11):e376-e380. View abstract
  22. Ultrasensitive CRISPR-based diagnostic for field-applicable detection of Plasmodium species in symptomatic and asymptomatic malaria. Proc Natl Acad Sci U S A. 2020 10 13; 117(41):25722-25731. View abstract
  23. Laxative Use Does Not Preclude Diagnosis or Reduce Disease Severity in Clostridiodes difficile Infection. Clin Infect Dis. 2020 09 12; 71(6):1472-1478. View abstract
  24. Assessment of the Clinical Utility of Plasma Metagenomic Next-Generation Sequencing in a Pediatric Hospital Population. J Clin Microbiol. 2020 06 24; 58(7). View abstract
  25. Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype. Clin Infect Dis. 2020 06 10; 70(12):2628-2633. View abstract
  26. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea. Clin Infect Dis. 2020 03 03; 70(6):1083-1093. View abstract
  27. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. J Clin Med. 2019 Dec 31; 9(1). View abstract
  28. Detection of mycobacterial lipoarabinomannan in serum for diagnosis of active tuberculosis. Diagn Microbiol Infect Dis. 2020 Feb; 96(2):114937. View abstract
  29. Correction to: Detection of Mycobacterium tuberculosis in pediatric stool samples using TruTip technology. BMC Infect Dis. 2019 10 16; 19(1):856. View abstract
  30. Detection of Mycobacterium tuberculosis in pediatric stool samples using TruTip technology. BMC Infect Dis. 2019 Jun 27; 19(1):563. View abstract
  31. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay. Clin Infect Dis. 2019 01 01; 68(1):78-86. View abstract
  32. Assessing the Burden of Clostridium difficile Infection in Low- and Middle-Income Countries. J Clin Microbiol. 2018 03; 56(3). View abstract
  33. Discovery of a unique Mycobacterium tuberculosis protein through proteomic analysis of urine from patients with active tuberculosis. Microbes Infect. 2018 04; 20(4):228-235. View abstract
  34. The Cost-effectiveness of a Point-of-Care Paper Transaminase Test for Monitoring Treatment of HIV/TB Co-Infected Persons. Open Forum Infect Dis. 2017; 4(4):ofx194. View abstract
  35. A novel device for collecting and dispensing fingerstick blood for point of care testing. PLoS One. 2017; 12(8):e0183625. View abstract
  36. Erysipelothrix rhusiopathiae Suppurative Arthritis in a 12-year-old Boy After an Unusual Fresh Water Exposure. Pediatr Infect Dis J. 2017 04; 36(4):431-433. View abstract
  37. Evaluating Novel Diagnostics in an Outbreak Setting: Lessons Learned from Ebola. J Clin Microbiol. 2017 05; 55(5):1255-1261. View abstract
  38. Diagnosis of Ebola Virus Disease: Past, Present, and Future. Clin Microbiol Rev. 2016 Oct; 29(4):773-93. View abstract
  39. Performance of the GeneXpert Ebola Assay for Diagnosis of Ebola Virus Disease in Sierra Leone: A Field Evaluation Study. PLoS Med. 2016 Mar; 13(3):e1001980. View abstract
  40. Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection. J Clin Microbiol. 2016 Feb; 54(2):259-64. View abstract
  41. Field Laboratory Evaluation of the GeneXpert Ebola Assay for Diagnosis of Ebola Virus Disease in Sierra Leone. Open Forum Infect Dis. 2015 Dec; 2(Suppl 1). View abstract
  42. ReEBOV Antigen Rapid Test kit for Ebola - Authors' reply. Lancet. 2015 Dec 05; 386(10010):2255-6. View abstract
  43. The Positive Predictive Value of Lyme Elisa for the Diagnosis of Lyme Disease in Children. Pediatr Infect Dis J. 2015 Nov; 34(11):1260-2. View abstract
  44. Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool. J Clin Microbiol. 2015 Oct; 53(10):3204-12. View abstract
  45. Paper-Based RNA Extraction, in Situ Isothermal Amplification, and Lateral Flow Detection for Low-Cost, Rapid Diagnosis of Influenza A (H1N1) from Clinical Specimens. Anal Chem. 2015 Aug 04; 87(15):7872-9. View abstract
  46. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet. 2015 Aug 29; 386(9996):867-74. View abstract
  47. Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples. PLoS One. 2015; 10(5):e0128118. View abstract
  48. Differential immunodetection of toxin B from highly virulent Clostridium difficile BI/NAP-1/027. J Clin Microbiol. 2015 May; 53(5):1705-8. View abstract
  49. Challenges in the development of an immunochromatographic interferon-gamma test for diagnosis of pleural tuberculosis. PLoS One. 2013; 8(12):e85447. View abstract
  50. Interferon ?-release assays for diagnosis of latent tuberculosis in healthcare workers in low-incidence settings: pros and cons. Clin Chem. 2014 May; 60(5):714-8. View abstract
  51. Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test. PLoS One. 2013; 8(9):e75616. View abstract
  52. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. Eur Respir J. 2013 Nov; 42(5):1427-9. View abstract
  53. A point-of-care paper-based fingerstick transaminase test: toward low-cost "lab-on-a-chip" technology for the developing world. Clin Gastroenterol Hepatol. 2013 May; 11(5):478-82. View abstract
  54. A Disposable Microfluidic Virus Concentration Device Based on Evaporation and Interfacial Tension. Diagnostics (Basel). 2013 Mar; 3(1):155-69. View abstract
  55. Validation of Mycobacterium tuberculosis Rv1681 protein as a diagnostic marker of active pulmonary tuberculosis. J Clin Microbiol. 2013 May; 51(5):1367-73. View abstract
  56. A point-of-care paper-based fingerstick transaminase test: toward low-cost "lab-on-a-chip" technology for the developing world. Clin Gastroenterol Hepatol. 2013; 5(11):478-82. View abstract
  57. Validation of Mycobacterium tuberculosis Rv1681 protein as a diagnostic marker of active pulmonary tuberculosis. J Clin Microbiol. 2013; 5(51):1367-73. View abstract
  58. A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med. 2012 Sep 19; 4(152):152ra129. View abstract
  59. Microfluidic chip for molecular amplification of influenza A RNA in human respiratory specimens. PLoS One. 2012; 7(3):e33176. View abstract
  60. Microfluidic chip for molecular amplification of influenza A RNA in human respiratory specimens. PLoS One. 2012; 3(7):e33176. View abstract
  61. Low yield of chest radiography in a large tuberculosis screening program. Radiology. 2010 Sep; 256(3):998-1004. View abstract
  62. Ruling out novel H1N1 influenza virus infection with direct fluorescent antigen testing. Clin Infect Dis. 2009 Sep 15; 49(6):e66-8. View abstract
  63. Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results. Infect Control Hosp Epidemiol. 2009 Apr; 30(4):392-5. View abstract
  64. Discordant QuantiFERON-TB Gold test results among US healthcare workers with increased risk of latent tuberculosis infection: a problem or solution? Infect Control Hosp Epidemiol. 2008 Sep; 29(9):878-86. View abstract
  65. Development of a Novel Urine Antigen Detection Test for Active Tuberculosis. 43rd Joint Tuberculosis/Leprosy Conference and Diagnostics Workshop . 2008. View abstract
  66. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. 2008 Jul; 153(1):56-62. View abstract
  67. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clin Vaccine Immunol. 2008 Apr; 15(4):638-43. View abstract
  68. Screening Health Care Workers (HCW) with Quantiferon-Gold: Possible False Negative Results in HCW with High Pre-Test Probability of Latent Tuberculosis Infection. Presented at the International Union Against Tuberculosis and Lung Disease (IUATLD) Conference and Global Symposium on Interferon-gamma Assays, Vancouver, Canada, February 2007. 2007. View abstract
  69. Specimen dilution increases the diagnostic utility of the gen-probe mycobacterium tuberculosis direct test. Am J Clin Pathol. 2006 Jul; 126(1):142-7. View abstract
  70. Reconstitution of membrane transport powered by a novel dimeric kinesin motor of the Unc104/KIF1A family purified from Dictyostelium. J Cell Biol. 1999 Nov 01; 147(3):493-506. View abstract
  71. Reconstitution of Microtubule-based Organelle Transport Using Factors Purified from Dictyostelium. 1999. View abstract
  72. In vitro microtubule-based organelle transport in wild-type Dictyostelium and cells overexpressing a truncated dynein heavy chain. Cell Motil Cytoskeleton. 1998; 40(3):304-14. View abstract